NEW YORK (GenomeWeb) – Roche announced this week that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta for $27 per share. The tender offer is being made pursuant to a merger agreement entered into by Ignyta and Roche on Dec. 21, and will expire on Feb. 7. Following successful completion of the tender offer, any shares not acquired will be acquired in a second step merger at the same price of $27 per share. The closing of the transaction is expected to take place in the first half of 2018.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.